Search Results - therapeutics+%3e+oncology+%3e+oncology+immunotherapy

38 Results

Sort By:

Methods to Improve Chimeric Antigen Receptor (CAR)-T Cell Efficacy Through Rational Sequence and Structural Modifications (UCLA Case No. 2020-497)

UCLA researchers in the Department of Microbiology, Immunology & Molecular Genetics have developed novel engineering methodologies for CAR molecules that overcome the tonic signaling process that leads to T cell exhaustion and poor therapy efficacy. Background: Immunotherapy has become a highly effective method to combat cancer that enhances a...

Published: 2/14/2025 | Inventor(s): Yvonne Chen

Keywords(s): Cancer Immunotherapy

Category(s): Therapeutics > Oncology > Oncology Immunotherapy

Functional Enrichment and Purification of a Therapeutically Superior Population of Cells (Case No. 2024-024)

Summary: UCLA researchers in the Departments of Bioengineering and Biological Chemistry have developed a method for identifying and enriching therapeutically useful cell sub-populations based on their secretions (SEC-seq). Background: Cell function is defined by a myriad of biomolecules that they secrete; over 3 thousand proteins are estimated to...

Published: 3/3/2025 | Inventor(s): Dino Di Carlo, Kathrin Plath, Shreya Udani, Justin Langerman

Keywords(s): Cell Surface Receptor, Cytometry, Flow Cytometry, Functional Genomics, High-Throughput Screening, hydrogel, Microfluidics, single cell analysis, Therapeutics

Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy, Life Science Research Tools, Life Science Research Tools > Research Methods, Diagnostic Markers > Targets And Assays, Therapeutics > Cell Therapy

Inhibitory Chimeric Antigen Receptors That Reduce Car-T Cell “On-Target, Off-Tumor” Toxicity (UCLA Case No. 2022-186)

SUMMARY: UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics, and the Department of Molecular and Medical Pharmacology have recently developed a novel approach which improves the kinetics and specificity of CAR T-cell therapy. BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy makes use of reengineered...

Published: 2/14/2025 | Inventor(s): Owen Witte

Keywords(s): blood cancers, CAR-T cell therapy

Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics

Inhibition of BMI1 Eliminated Cancer Stem Cells and Activates Antitumor Immunity (UCLA Case No. 2020-858)

UCLA researchers in the Department of Dentistry discovered that targeting BMI1in head and neck squamous cell carcinoma (HNSCC) may be a viable immune checkpoint to inhibit metastatic tumor growth, and prevent tumor relapse through activation of cell-intrinsic immunity and purging cancer stem cells (CSCs). BACKGROUND: Cancer stem cells are cancer...

Published: 2/14/2025 | Inventor(s): Cun Yu Wang, Jia Lingfei

Keywords(s): Cancer stem cells, Epigenetics, Immunooncology, Oncology Immunotherapy, Tumor

Category(s): Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Gene Therapy And Editing

Targeting Prostate Cancer with a Novel T-Cell Receptor and Tissue-Specific Cancer Antigens for Improved Immune Response (UCLA Case No. 2022-070)

Researchers from UCLA’s Department of Microbiology, Immunology, & Molecular Genetics (MIMG), and the department of Molecular and Medical Pharmacology have identified a set of tissue-specific antigens which have been used to isolate and characterize a group of novel T-cell receptors (TCRs) which target prostate cancer specifically. Furthermore,...

Published: 2/14/2025 | Inventor(s): Owen Witte, Zhiyuan Mao, Jami Witte, Pavlo Nesterenko, John Lee

Keywords(s): Cancer, cancer antigen, Peptide, peptides, prostate cancer, protein, t-cells

Category(s): Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Antitumor activity of NKTR-214 alone or in combination with anti-PD-1 therapy in tumors resistant to anti-PD-1 (UCLA Case No. 2019-254)

UCLA researchers have discovered a therapy for anti-PD-1 resistant tumors in colon carcinoma patients. A small molecule therapeutic alone or in combination with immune-checkpoint blockade (ICB) therapy exhibits tumor remission even in sublines with mutated signalling pathways that have rendered them ICB resistant. BACKGROUND: Immunotherapy, the...

Published: 2/14/2025 | Inventor(s): Antoni Ribas

Keywords(s): Colon carcinoma, Immune checkpoint blockade, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), PD-1, PD-L1, Resistant tumors, Signaling pathways, Small molecule therapeutics, Tumor

Category(s): Life Science Research Tools, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

Combination of Supercharged NK with Supercharged Gamma Delta T Cells and Supercharged CD8+ T Cells and Super Charged iNKT Cells Should Eliminate Both (UCLA Case No. 2022-322)

SUMMARY: Researchers at UCLA’s School of Dentistry have developed methods and protocols for culturing and priming various immune cells into a “supercharged” phenotype. The studied cell types include NK and iNKT cells, gamma delta T cells, and CD8+ T cells. When deployed in combination, these supercharged cells were found to eliminate...

Published: 2/14/2025 | Inventor(s): Anahid Jewett

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

2022-129 Development of Nano-Delivered CXCR4 Antagonist Carrier to Affect Tumor Microenvironment

SUMMARY: UCLA researchers in the David Geffen School of Medicine have developed a nanocarrier platform to deliver drugs that block CXCR4 directly in tumor microenvironments, with an impact on immune cell trafficking and reducing the tumor’s metastatic burden. BACKGROUND: Cancer remains among the leading causes of death worldwide, and its burden...

Published: 2/14/2025 | Inventor(s): Andre Nel

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

2023-043: Enhanced Gamma Delta T Cells for Immunotherapy

SUMMARY: UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics have developed a novel platform to generate potent, high quality Vδ2 T cells at scale for use in cancer immunotherapies. BACKGROUND: With rising cases of cancer in the world, immunotherapies have emerged as a promising and potentially effective therapeutic...

Published: 2/14/2025 | Inventor(s): Lili Yang

Keywords(s):

Category(s): Therapeutics, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

2022-190 Pharmacological Modulation of Chimeric Antigen Receptor (CAR)-T Cell Signaling Pathways to Improve Tumor-Killing Efficacy

SUMMARY: UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics have developed a novel chimeric antigen receptor (CAR)-T cell manufacturing process to prevent premature CAR-T cell dysfunction and enhance CAR-T cell durability and potency. BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy is an emerging pillar...

Published: 2/14/2025 | Inventor(s): Yvonne Chen

Keywords(s):

Category(s): Therapeutics, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

1 2 3 4